Kristina Masson - Nov 9, 2022 Form 3 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
EVP - Business Operations, Director
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Stock symbol
ACRV
Transactions as of
Nov 9, 2022
Transactions value $
$0
Form type
3
Date filed
11/9/2022, 07:30 PM
Next filing
Nov 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ACRV Common Stock 294K Nov 9, 2022 Direct
holding ACRV Common Stock 872K Nov 9, 2022 See footnote. F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ACRV Stock Option (Right to Buy) Nov 9, 2022 Common Stock 83K $1.04 Direct F2
holding ACRV Stock Option (Right to Buy) Nov 9, 2022 Common Stock 62.2K $3.88 Direct F3
holding ACRV Stock Option (Right to Buy) Nov 9, 2022 Common Stock 166K $1.04 See footnote. F1, F2
holding ACRV Stock Option (Right to Buy) Nov 9, 2022 Common Stock 124K $3.88 See footnote. F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held by Dr. Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
F2 Twenty-five percent (25%) of the shares subject to the option vested on October 5, 2020, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
F3 The shares subject to the option vested or shall vest quarterly on the last day of each quarter for 16 quarters following January 1, 2022, in each case subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney